Bitget App
Mag-trade nang mas matalino
Buy cryptoMarketsTradeFuturesEarnSquareMore
Price
Data
About
IQV stock price forecast
News
Competitors
Tokenization
Crypto
FAQ
IQVIA Holdings, Inc. stock logo

IQVIA Holdings, Inc.

IQV·NYSE

Huling na-update noong 2026-02-13 06:18 EST. Ang impormasyon sa presyo ng stock ay nagmumula sa TradingView at sumasalamin sa real-time market prices.

Insights
Calculator
News

IQV stock price change

Sa huling araw ng trading, IQV sarado ang stock sa 166.50 USD, na may pagbabago sa presyo ng -6.03% para sa araw.
Trade stock futures

Tungkol kay Bitget

Ang unang Universal Exchange (UEX) sa mundo, na nagbibigay-daan sa mga gumagamit na mag-trade hindi lamang ng mga cryptocurrency, kundi pati na rin ng mga stock, ETF, forex, gold, at mga real-world asset (RWA).
Learn more

IQV key data

Previous close166.50 USD
Market cap28.35B USD
Volume1.94M
P/E ratio21.19
Dividend yield (TTM)0.00%
Dividend amount-
Last ex-dividend date-
Last payment date-
EPS diluted (TTM)7.86 USD
Net income (FY)1.36B USD
Revenue (FY)16.31B USD
Next report dateApr 23, 2026
EPS estimate2.830 USD
Revenue estimate4.09B USD USD
Shares float168.74M
Beta (1Y)0.94
Tokenized stocks

Nakarinig ka na ba ng tungkol sa mga tokenized stock?

Isang bagong paraan ng trade stocks — anumang oras, kahit saan, 24/7.

Learn more

IQVIA Holdings, Inc. overview

Ang IQVIA Holdings, Inc. ay nagbibigay ng analytics, mga solusyon sa teknolohiya, at mga serbisyo sa klinikal na pananaliksik para sa industriya ng life sciences. Ito ay may mga sumusunod na segment: Technology and Analytics Solutions, Research and Development Solutions, at Contract Sales and Medical Solutions. Ang Technology and Analytics Solutions segment ay naglalaan ng mahahalagang impormasyon, teknolohikal na solusyon, at mga real-world na serbisyo sa mga kliyente ng kompanya sa larangan ng life sciences. Ang Research and Development Solutions segment ay nagbibigay ng outsourced na klinikal na pananaliksik at mga serbisyong may kaugnayan sa clinical trials. Ang Contract Sales and Medical Solutions segment ay nag-aalok ng mga serbisyo para sa pakikipag-ugnayan ng mga healthcare provider at pasyente sa mga biopharmaceutical na kliyente at sa healthcare market. Ang kompanya ay itinatag nina Dennis B. Gillings at Gary Koch noong 1982 at ang punong-tanggapan ay nasa Durham, NC.
Sector
Teknolohiyang pangkalusugan
Industry
Bioteknolohiya
CEO
Ari Bousbib
Headquarters
Durham
Website
iqvia.com
Founded
1950
Employees (FY)
-
Change (1Y)
-
Revenue / Employee (1Y)
-
Net income / Employee (1Y)
-

IQV Pulse

Daily updates on IQV stock prices, fund flows, and market news, generated by AI and reviewed by our team of analysts. Always DYOR.

• IQV Pagbabago ng Presyo ng Stock sa loob ng 24h: -2.89%. Mula $182.45 USD pababa sa $177.18 USD. Nakaranas ang stock ng matinding pagbebenta sa mataas na volume, na pangunahing dulot ng hindi kahanga-hangang 2026 revenue guidance na $17.15B–$17.35B at kamakailang insider selling activity, sa kabila ng paglagpas sa Q4 2025 earnings estimates.
• Mula sa teknikal na pananaw, nagpapakita ang merkado ng "Malakas na Pagbebenta" na signal sa panandaliang panahon. Ang stock ay bumagsak sa ibaba ng 50-day moving average ($225.42) at 200-day moving average ($209.47), na may RSI (14) na 36.18, papalapit sa oversold territory ngunit nagpapahiwatig ng malakas na bearish momentum kasunod ng pagbaba dulot ng guidance.
• Nag-ulat ang IQVIA ng Q4 2025 earnings na $3.42 kada share, na lumampas sa mga inaasahan, ngunit bumagsak ang shares dahil nabigo ang 2026 guidance na mapanatili ang kumpiyansa ng mga investor at nagpakita ng katamtamang paglago.
• Inanunsyo ng IQVIA at Duke Clinical Research Institute ang isang estratehikong kolaborasyon upang isulong ang clinical research sa obesity at cardiometabolic conditions, na layuning gamitin ang global trial operations.
• Ang mga senior executive, kabilang ang CEO, ay lumahok sa regular na insider equity activity; gayunpaman, ang ilang bentahan sa $187.49 kasunod ng vesting ng performance units ay nagdagdag ng pag-iingat sa merkado.
• Iniulat na isinasaalang-alang ng FDA ang pagbabago sa mga kinakailangan sa pag-apruba ng gamot na maaaring magpababa ng bilang ng mga kinakailangang trial, isang hakbang na nagdulot ng pagbaba sa shares ng mga pangunahing CRO (Contract Research Organizations) dahil sa posibleng epekto sa volume.
• Inanunsyo ng Charles River Laboratories, isang pangunahing kakumpitensya sa CRO space, ang pagsasara ng isang CDMO site at mga tanggalan, na sumasalamin sa mas mahigpit na kapaligiran sa paggastos ng biopharma R&D.
See more
about 19h ago
• Pagbabago sa presyo ng IQV Stock sa loob ng 24h: -1.66%. Mula $192.67 USD naging $189.48 USD. Ang pagbaba ay kasunod ng malaking pagbebenta matapos ang earnings sa simula ng linggo, habang tinimbang ng mga investor ang malakas na Q4 results laban sa babala ng mas mataas na interest expenses at margin pressures para sa 2026.
• Sa teknikal na pananaw, nagpapakita ang IQV ng "bearish breakdown na may oversold potential": ang stock ay nagte-trade sa ilalim ng 50-day ($231) at 200-day ($209) moving averages, na nagpapahiwatig ng malakas na downward trend. Habang ang 14-day RSI (approx. 36) ay papalapit sa oversold territory, ipinapakita ng MACD at iba pang oscillators ang patuloy na selling pressure sa malapit na panahon.
• Inanunsyo ng IQVIA at Duke Clinical Research Institute noong Pebrero 10 ang isang strategic collaboration upang paunlarin ang clinical research sa obesity at mga kaugnay na metabolic conditions, gamit ang AI-driven data capabilities ng IQVIA.
• Noong Pebrero 9, isiniwalat ng Optimas Capital Ltd ang bagong $4.01 milyon na investment sa IQVIA, nagpapakita ng institutional confidence sa kabila ng kamakailang price volatility at mixed analyst target revisions kasunod ng FY2026 guidance.
• Kamakailan, tinapos ng U.S. at India ang isang trade deal na nagpapababa ng tariffs sa Indian pharma at medtech exports mula 50% hanggang 18%, layuning palakasin ang global supply chain at bawasan ang pagdepende sa ibang rehiyon para sa generic medications.
• Inilunsad ng U.S. FDA ngayong linggo ang "PreCheck" pilot program upang pabilisin ang konstruksyon at regulatory review ng domestic drug manufacturing facilities, binibigyang-priyoridad ang mga planta na gumagawa ng critical medications.
See more
about 1D ago

IQV stock price forecast

According to technical indicators for IQV stock, the price is likely to fluctuate within the range of 194.60–217.50 USD over the next week. Market analysts predict that the price of IQV stock will likely fluctuate within the range of 140.64–247.33 USD over the next months.

Based on 1-year price forecasts from 67 analysts, the highest estimate is 364.41 USD, while the lowest estimate is 210.28 USD.

For more information, please see the IQV stock price forecast Stock Price Forecast page.

Sa isang Bitget account lang, maaari kang mag-trade ng mga stock at cryptocurrencies nang sabay.

Join now!

FAQ

What is the stock price of IQVIA Holdings, Inc.?

IQV ay kasalukuyang nakapresyo sa 166.50 USD — ang presyo nito ay nagbago ng -6.03% sa nakalipas na 24 na oras. Maaari mong subaybayan ang pagganap ng presyo ng stock ng IQVIA Holdings, Inc. mas malapit sa chart ng presyo sa tuktok ng pahinang ito.

What is the stock ticker of IQVIA Holdings, Inc.?

Depende sa exchange, maaaring mag-iba ang stock ticker. Halimbawa, sa NYSE, IQVIA Holdings, Inc. ay tini-trade sa ilalim ng ticker IQV.

What is the stock forecast of IQV?

Nagtipon kami ng mga opinyon ng mga analyst tungkol sa IQVIA Holdings, Inc.future price. Ayon sa kanilang mga pagtataya, IQV ay may pinakamataas na pagtatantya ng 1665.00 USD at isang minimum na pagtatantya ng 333.00 USD.

What is the market cap of IQVIA Holdings, Inc.?

IQVIA Holdings, Inc. ay may market capitalization ng 28.35B USD.

What is P/E ratio (TTM)?

The P/E ratio (TTM) stands for price-to-earnings ratio (trailing twelve months). It is a historical valuation metric calculated using a company's earnings per share (EPS) over the most recent twelve consecutive months, reflecting the company's past profitability.

The P/E ratio measures the relationship between a stock's price and a company's profitability, and is often used as a basis for judging whether a stock is "cheap" or "expensive."

P/E ratio = market price (P) ÷ earnings per share (EPS), or P/E ratio = total market capitalization ÷ net profit attributable to shareholders

The interpretation of the P/E ratio (TTM) should always be considered alongside other factors and is mainly used for valuation comparisons rather than as a standalone indicator.

  • A lower P/E ratio (TTM) means investors are paying less for each unit of earnings. This may indicate that the stock is undervalued, or that the market has limited expectations for the company's future growth, such as in mature or slow-growing industries.
  • A higher P/E ratio (TTM) means investors are paying more for each unit of earnings. This often reflects expectations of strong future earnings growth, which is common among growth or technology stocks, though it may also suggest the stock is overvalued.
  • Comparison with peers: Compare the company's P/E (TTM) with the average or median P/E of other companies in the same industry. A significantly higher P/E may require further analysis to determine whether the company's high valuation is justified by stronger growth prospects or competitive advantages.
  • Comparison with historical levels: Compare the company's current P/E (TTM) with its own historical average (such as over the past 5 or 10 years) to assess whether the current valuation is at a historical high or low.
  • Comparison with the broader market: Compare the company's P/E (TTM) with major market indices (such as the S&P 500) to see how the market is valuing the company overall.

P/E ratios can vary widely across industries, and there is no single "ideal" P/E level. A reasonable P/E range depends on the industry, the company's growth potential, and the broader macroeconomic environment. Investment decisions should not rely solely on the P/E ratio (TTM) but should be based on a comprehensive analysis that includes company quality, growth prospects, and financial health.

Can I trade stocks on Bitget?

You can trade stocks on Bitget, but mainly through stock tokens and stock perps, rather than by directly buying or selling traditional stocks.

This approach reflects Bitget's vision as a Universal Exchange (UEX), designed to connect traditional financial markets with cryptocurrency markets.

Bitget currently offers the following stock-related trading formats:

1. Stock tokens (spot)

Nature: Stock tokens are digital tokens pegged to the price of specific traditional stocks (such as TSLAUSDT and NVDAUSDT) and are traded on Bitget's spot market.

Features: When you trade stock tokens, you are buying and holding tokens rather than owning the underlying traditional stocks.

  • The price of these tokens generally follows the price movements of the stocks they are pegged to, such as Tesla or Nvidia.
  • The advantage is that you can participate in the price movements of traditional financial assets, such as U.S. stocks, using cryptocurrencies (for example, USDT), without the need for a traditional brokerage account.

2. Stock perps

Nature: Bitget also offers USDT-margined perpetual futures, commonly referred to as stock perps, based on major U.S. blue-chip stocks such as Tesla and Meta.

Characteristics: Stock perps are derivative products that allow you to take a bullish or bearish view on the future price of an underlying stock through margin trading. These products typically support leverage, such as up to 25x.

It does not involve owning the underlying stock. Instead, profits and losses are settled based on price movements of the futures.

Important note: When trading stock perps on Bitget, you are participating in derivative markets within the cryptocurrency ecosystem. This is fundamentally different from purchasing publicly traded shares through a traditional brokerage, as you do not own equity in the underlying company.

Futures trading and the use of leverage involve high risk. Please ensure you fully understand the risks before trading.

If you wish to directly hold equity in traditional stocks and enjoy shareholder rights (such as receiving dividends), you must trade through a regulated traditional securities brokerage or brokerage platform.

What are the advantages of Bitget's stock perps?

Bitget's stock perps—typically perpetual futures based on stock tokens prices—are an innovative offering that allows cryptocurrency platforms to provide exposure to traditional financial markets.

Compared to traditional stock or futures trading, they offer several unique advantages, primarily due to the platform's trading infrastructure.

Bitget's stock perps, typically USDT-denominated derivatives, offer the following key advantages:

1. Trading convenience and global accessibility

  • 24/7 trading: Traditional stock markets, such as U.S. equity markets, operate during fixed trading hours. In contrast, cryptocurrency derivatives markets are typically open 24/7. This means investors can trade anytime, capitalizing on breaking news or market fluctuations.
  • Lower entry barriers and faster onboarding: Compared with traditional brokerages, which often require extensive identity verification and lengthy account setup processes, Bitget generally offers faster account onboarding. Users can trade using cryptocurrencies such as USDT, without the need for complex fiat deposit and withdrawal procedures.
  • Global accessibility: Users can access derivatives trading linked to globally recognized stocks via the Bitget platform, subject to applicable regulations.

2. Capital efficiency and high leverage

  • High leverage options: Stock perps typically offer higher leverage than traditional stock trading (for example, up to 25x). This allows traders to control larger positions with smaller margin requirements, improving capital efficiency.
    Note: While high leverage can amplify gains, it also amplifies losses proportionally.
  • Two-way trading: Traders can easily take both long and short positions. This means traders can potentially profit from market volatility whether stock prices rise or fall, provided the market direction is correctly anticipated.

3. Trading and settlement using cryptocurrency

  • USDT margin: Stock perps on Bitget typically use USDT (or other stablecoins) as the margin and settlement currency. For users who already hold cryptocurrency, there is no need to convert assets into fiat currency, allowing them to trade directly with stablecoins.
  • Efficient fund transfers: Crypto-based transfers and settlements are typically faster than traditional fiat systems, enabling more efficient global fund allocation.

4. Integration

One-stop platform: Bitget allows users to trade spot cryptocurrencies, crypto derivatives, and stock perps on a single platform, making it easier to manage different asset types in one place.

Risk warning:

While Bitget's stock perps offer several advantages, it is important to understand the associated risks.

  • High leverage risk: Leveraged trading can result in rapid loss of your entire margin.
  • No equity ownership: When trading stock perps, you do not own the underlying shares. As a result, you are not entitled to dividends or voting rights.
  • Market liquidity risk: Tokenized stock perps may have lower liquidity than their counterparts in traditional stock markets, especially outside regular trading hours.

In summary, Bitget's stock perps offer advantages such as greater trading flexibility, lower entry barriers, and higher capital efficiency.

What are the trading fees for Bitget stock perps?

Trading fees for Bitget stock perps (USDT-margined perpetual futures) mainly include transaction fees and funding rates.

Transaction fees:

Bitget offers limited-time fee promotions for stock perps (especially tokenized stock perps) from time to time to attract traders.

Standard reference rates: Under Bitget's standard futures fee structure, the taker fee is typically around 0.06%, while the maker fee is around 0.02%.

Current promotions for stock perps (important): To promote its stock perps products, Bitget is offering discounted transaction fees during Q4 2025, with taker fees as low as 0.006% and maker fees as low as 0.002%. There is also a limited-time promotion offering zero-fee trading for spot stock tokens.

Recommendation: Since promotional activities are subject to change or end at any time, please visit Bitget's official " Fee overview " or " Announcement Center " page for the latest and most accurate rates at the time of trading.

Funding rate:

The funding rate is a key mechanism in perpetual futures (including stock perps) that helps keep the futures price closely aligned with the spot price of the underlying asset. It is not a fee charged by the platform, but a periodic payment exchanged between long and short traders.

Funding rates fluctuate dynamically and are mainly driven by market sentiment and imbalances between long and short positions. Stock perps generally experience lower volatility than cryptocurrencies, so funding rates are often relatively low during stable market conditions. However, during earnings seasons or major positive or negative news events, heavy concentration of long or short positions—such as in high-growth technology stocks like Tesla or Nvidia—can create significant imbalances, causing funding rates to spike in the short term.

Funding payments are typically settled every 8 hours. If you close your position before the funding settlement time, no funding payment will be charged or received.

Funding rates are not fixed. If you hold a position for an extended period, high positive funding rates (for long positions) or high negative funding rates (for short positions) will affect your overall holding costs or potential returns. For this reason, it is important to monitor the funding rate in real time on the trading interface.

NYSE/
IQV